| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 13
Oral Abstracts Antiretroviral Therapy: Emergence, Mechanisms, and Persistence of Resistance Monday, 4 - 6:15 pm Room 3000 |
| Moderators | Joep Lange Intl Antiviral Therapy Evaluation Ctr, Academic Med Ctr, Univ of Amsterdam, The Netherlands Mary Albrecht Beth Israel Deaconess Med Ctr, Boston, MA, USA |
| 4:00 pm 51 | Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of Didanosine, Lamivudine, and Tenofovir DF J Jemsek*, P Hutcherson, and E Harper Jemsek Clin., Huntersville, NC, USA |
| 4:15 pm 52 | Low Genetic Barrier to Resistance Is a Possible Cause of Early Virologic Failures in Once-Daily Regimen of Abacavir, Lamivudine, and Tenofovir: The Tonus Study R Landman*1, G Peytavin1, D Descamps1, F Brun Vezinet1, H Benech1,8, A Benalisherif1,2, A Trylesinski2,3, C Katlama3,4, P M Girard4,5, F Raffi1, P Yeni6, M Bentata6, B Jarrousse6,7, C Michelet7,8, P Flandre9, Tonus Study Group, and Tonus study group 1Bichat Claude Bernard Hosp., Paris, France; 2Gilead Sci., Paris, France; 3Pitié-Salpêtrière Hosp., Paris, France; 4Saint Antoine Hosp., Paris, France; 5CHU Nantes, Hosp. Nantes, France; 6Avicennes Hosp., Bobigny, France; 7CHU Rennes, France; 8CEA Lab., Orsay, France; and 9Inserm U472. Villejuif, France |
| 4:30 pm 53 | COL40263: Resistance and Efficacy of Once-daily Trizivir and Tenofovir DF in Antiretroviral Naïve Subjects R Elion*1, C Cohen2, E DeJesus3, R Redfield4, J Gathe5, R Hsu6, L Yau7, L Ross7, B Ha7, R Lanier7, T Scott7, and COL40263 study team 1George Washington Sch. of Med., Washington DC, USA; 2Community Res. Initiative of New England, Boston, MA, USA; 3IDC Res. Initiative, Altamonte Springs, FL, USA; 4Inst. of Human Virology, Baltimore, MD, USA; 5Therapeutic Concepts, P.A., Houston, TX, USA; 6St. Vincent's Hosp., New York, NY, USA; and 7GlaxoSmithKline, Research Triangle Park, NC, USA |
| 4:45 pm 54 | K65R: A Multinucleoside Resistance Mutation of Increasing Prevalence Exhibits Bi-directional Phenotypic Antagonism with TAM U Parikh*1, D Koontz1, N Sluis-Cremer1, J Hammond2, L Bacheler3, R Schinazi4, and J Mellors1 1Univ. of Pittsburgh, PA, USA; 2Agouron Pharm., La Jolla, CA, USA; 3VircoLab Inc., Durham, NC, USA; and 4Emory Univ., Atlanta, GA, USA |
| 5:00 pm 55 | The HIV-1 K65R RT Mutant Utilizes a Combination of Decreased Incorporation and Decreased Excision to Evade NRTI K L White*1, N A Margot1, J M Chen1, R Wang1, M Pavelko1, T Wrin2, C J Petropoulos2, M McDermott1, S Swaminathan1, and M D Miller1 1Gilead Sci., Inc., Foster City, CA, USA and 2ViroLogic Inc., South San Francisco, CA, USA |
| 5:15 pm 56 | Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1-infected Adults with Plasma HIV RNA <500 Copies/mL S Hammer*1, R Bassett2, M Fischl3, K Squires4, L Demeter5, J Currier6, G Morse7, V DeGruttola2, C Lalama2, S Snyder8, J Mellors9, ACTG 372A Study Team10, and Adult AIDS Clinical Trials Group 1Columbia Univ., New York, NY, USA; 2Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Univ. of Miami, FL, USA; 4Univ. of Southern California, Los Angeles, USA; 5Univ. of Rochester, NY, USA; 6Univ. of California, Los Angeles, USA; 7State Univ. of New York, Buffalo, NY; 8AACTG Operations Ctr., Rockville, MD, USA; 9Univ. of Pittsburgh, PA, USA; and 10NIAID-sponsored AACTG, Bethesda, MD, USA |
| 5:30 pm 57 | Detection of Pre-existing Minority Viral Populations Contributing to the Evolution of Resistance to Protease Inhibitors C Charpentier1, L Morand-Joubert2, G Chêne3, P-M Girard2, F Clavel1, and A J Hance*1 1INSERM U552, Paris, France; 2Hosp. Saint-Antoine, Paris, France; and 3INSERM U593, Bordeaux, France |
| 5:45 pm 58 | A 16-week Treatment Interruption Does Not Improve the Virologic Response to Multidrug Salvage Therapy in Treatment-experienced Patients: 48-week Results from ACTG A5086 C Benson*1, G Downey2, D V Havlir3, F Vaida2, M Lederman4, R Gulick5, M Glesby5, S Patel6, M Wantman2, C Bixby6, C Pettinelli7, A Rinehart9, S Snyder8, J Mellors6, and the ACTG A5086 Study Team 1Univ. of Colorado Hlth. Sci. Ctr., Denver, USA; 2Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3San Francisco Gen. Hosp., CA, USA; 4Case Western Reserve Univ., Cleveland, OH, USA; 5Weill Med. Coll. of Cornell Univ., New York, NY, USA; 6Univ. of Pittsburgh, PA, USA; 7NIAID, NIH, DHHS, Bethesda, MD, USA; 8Social and Sci. Systems, Inc., Silver Spring, MD, USA; and 9VircoLab Inc., Tibotec-Virco, Durham, NC, USA |
| 6:00 pm 59 | HIV-1 Subtype-related Differences in Genotypic Evolution: Analysis of Subtypes B and C Reverse Transcriptase and Protease Sequences R Kantor*1, R W Shafer1, B Efron1, R Camacho2, P R Harrigan3, A Tanuri4, D Pillay5, J Weber6, A M Vandamme7, P Phanuphak8, W Sugiura9, V Soriano10, L Morris11, J M Schapiro1, D Katzenstein1, and The International Non-subtype B Workging Group 1Stanford Univ., CA, USA; 2Hosp. Egas Moniz, Lisbon, Portugal; 3British Columbia Ctr. for Excellence in HIV/AIDS, Vancouver, Canada; 4Federal Univ. of Rio de Janeiro, Brazil; 5PHLS, Univ. of Birmingham, UK; 6Wright Fleming Inst., London, UK; 7Rega Inst. for Med. Res., Leuven, Belgium; 8Chulalongkorn Univ., Bangkok, Thailand; 9Natl. Inst. of Infectious Diseases, Tokyo, Japan; 10Hosp. Carlos III, Madrid, Spain; and 11Natl. Inst. for Virology, Johannesburg, South Africa |